Rhea Jeffers, APRN
Family · Englewood, OHNPI 1528429602
Payments from drug & device makers
Across 1,256 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$4K
- Johnson & Johnson$3K
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$3K
- Vanda Pharmaceuticals Inc.$3K
- Axsome Therapeutics, Inc.$2K
- plus $8K from 26 others
What the payments were for
- Food & beverage$27,193100%
- Education$550%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 214 | $4,339 |
| Johnson & Johnson | 78 | $3,476 |
| AbbVie | 254 | $3,306 |
| Teva Pharmaceuticals USA, Inc. | 139 | $3,245 |
| Vanda Pharmaceuticals Inc. | 104 | $2,559 |
| Axsome Therapeutics, Inc. | 83 | $2,357 |
| Alkermes, Inc. | 80 | $1,593 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 56 | $1,289 |
| Lundbeck LLC | 70 | $945 |
| Sunovion Pharmaceuticals Inc. | 52 | $925 |
| E.r. Squibb & Sons, L.L.C. | 29 | $802 |
| Gilead | 4 | $389 |
| Idorsia Pharmaceuticals US Inc | 15 | $296 |
| Validus Pharmaceuticals LLC | 2 | $256 |
| Noven Therapeutics, LLC | 13 | $233 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $207 |
| Neurocrine Biosciences, Inc. | 13 | $200 |
| Ironshore Pharmaceuticals Inc. | 1 | $118 |
| Biogen | 6 | $110 |
| Viiv Healthcare Company | 1 | $96 |
| Theratechnologies Inc. | 1 | $77 |
| Indivior Inc. | 4 | $76 |
| Corium, LLC | 6 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $60 |
| Tempus AI, Inc | 3 | $52 |
| Bausch Health US, LLC | 3 | $41 |
| Tris Pharma Inc | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $24 |
| Braeburn Inc. | 1 | $23 |
| Neuronetics, Inc. | 1 | $14 |
| Tonix Medicines, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,287
- SPRAVATO$932
- AUSTEDO$726
- ABILIFY MAINTENA$495
- Auvelity$484
- COBENFY$453
- VRAYLAR$447
- Fanapt$375
- Austedo XR$373
- INVEGA SUSTENNA$371
- REXULTI$370
- Equetro$256
- CAPLYTA$252
- INVEGA TRINZA$250
- ABILIFY ASIMTUFII$247
- UZEDY$246
- Epclusa$122
- JORNAY PM$118
How this compares
$27,248 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 21 | $191,295 |
| VraylarCariprazine Hcl | 78 | $121,129 |
| Abilify AsimtufiiAripiprazole | 11 | $60,307 |
| Abilify MaintenaAripiprazole | 16 | $43,855 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $36,918 |
| TrintellixVortioxetine Hydrobromide | 65 | $33,055 |
| RexultiBrexpiprazole | 18 | $24,408 |
| Lurasidone Hcl | 58 | $23,873 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 32 | $6,679 |
| Buspirone Hcl | 251 | $4,071 |
| Atomoxetine Hcl | 43 | $3,825 |
| Doxepin Hcl | 174 | $3,809 |
| Bupropion Hcl SrBupropion Hcl | 212 | $3,609 |
| Duloxetine Hcl | 158 | $3,589 |
| Clonazepam | 355 | $3,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $3,245 | $191,29521 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena, Rexulti | $4,339 | $128,57045 claims |
| AbbVieVraylar | $3,306 | $121,12978 claims |
| Alkermes, Inc.Lybalvi | $1,593 | $36,91822 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $207 | $33,05565 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Englewood
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.